INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a debilitating neurodegenerative disease that causes degeneration of upper and lower motor neurons, which leads to paralysis, respiratory failure, and death (Rowland and Shneider, 2001) . Frontotemporal dementia (FTD) is a type of early onset dementia caused by degeneration of the frontal and anterior temporal lobes causing cognitive deficits and behavioral and language abnormalities (McKhann et al., 2001) . Symptoms include loss of empathy, stereotypic behavior, apathy, and/or disinhibition. A hexanucleotide (GGGGCC, G4C2) repeat expansion in an intron of C9orf72 is the most frequent reported genetic cause of ALS and FTD (DeJesus-Hernandez et al., 2011; Renton et al., 2011) . This discovery was exciting because it genetically linked ALS and FTD to each other and to a larger group of microsatellite expansion diseases (Cleary and Ranum, 2014) . Building on research from other microsatellite diseases (Cleary and Ranum, 2013; Goodwin and Swanson, 2014; Orr and Zoghbi, 2007; Ranum and Cooper, 2006) , several possible disease mechanisms have emerged for C9orf72 ALS/FTD, including (1) loss of function of the C9orf72 protein caused by haploinsufficiency of C9orf72 mRNA in patients with expansions (DeJesus-Hernandez et al., 2011) ; (2) RNA gain of function in which sense or antisense expansion RNAs (DeJesus-Hernandez et al., 2011; Zu et al., 2013) sequester one or more RNA binding proteins, compromising their physiological function (Freibaum et al., 2015; Goodwin and Swanson, 2014; Jovi ci c et al., 2015; Zhang et al., 2015) ; and (3) repeat-associated non-ATG (RAN) translation (Zu et al., 2011) of the expansion RNAs, which gives rise to six RAN proteins (poly-GlyAla [GA] , poly-GlyArg [GR] , and poly-GlyPro [GP] in the sense direction, and poly-GlyPro [GP] , poly-ProArg [PR] , and poly-ProAla [PA] in the antisense direction) that accumulate in human C9(+) autopsy tissue (Ash et al., 2013; Mori et al., 2013; Zu et al., 2013) .
A number of models have been generated to understand the molecular events that lead to C9orf72 ALS/FTD (Ciura et al., 2013; Freibaum et al., 2015; Jovi ci c et al., 2015; Kwon et al., 2014; Lagier-Tourenne et al., 2013; Mizielinska et al., 2014; Suzuki et al., 2013; Therrien et al., 2013; Zhang et al., 2015) . Knockout of the C9orf72 ortholog (3110043O21Rik) at embryonic day (E)10.5 in neurons and glia failed to cause neurodegenerative changes, arguing that C9orf72 loss of function is not sufficient to cause disease (Koppers et al., 2015) . Further support for a gain-of-function mechanism is provided by adeno-associated virus (AAV)-mediated overexpression of a minigene containing 66 G4C2 repeats in mice that leads to mild neurodegeneration in the cortex and cerebellum, but not the severe phenotypes and paralysis found in ALS/FTD (Chew et al., 2015) . While there is growing evidence that overexpression of C9orf72 RNAs or RAN proteins can cause gain-of-function effects (Chew et al., 2015; Kwon et al., 2014; Mizielinska et al., 2014; Wen et al., 2014) , there is an urgent need for a transgenic mouse that develops the clinical and neurodegenerative features of ALS/FTD by driving sense and antisense gene expression at levels and in spatial/temporal expression patterns found in patients. Recently, two groups reported the development of C9orf72 bacterial artificial chromosome (BAC) transgenic mouse models that accumulate RAN proteins and RNA foci but do not develop the clinical features of ALS/FTD (O'Rourke et al., 2015; Peters et al., 2015) .
Here, we describe a novel BAC transgenic mouse model containing the full-length C9orf72 gene and substantial flanking sequence to drive expression of sense and antisense transcripts using the endogenous human promoters. In contrast to other C9orf72 mouse models (Chew et al., 2015; O'Rourke et al., 2015; Peters et al., 2015; Suzuki et al., 2013) , our mice show decreased survival as well as phenotypic, neuropathological, and molecular hallmarks of C9orf72 ALS/FTD.
RESULTS

Generation of C9orf72 BAC G4C2 Expansion Mice
To understand the molecular mechanisms and disease course of C9orf72 ALS/FTD, we developed a BAC transgenic mouse model. The BAC construct shown in Figure 1A was selected for pronuclear injection because it contains the full-length human C9orf72 gene and no other annotated genes. PCR amplification and sequencing using the pCC1-F and pCC1-R primers (Table S1 , available online) were performed to identify the 5 0 and 3 0 ends of the BAC insertion, which showed the 002:B7 BAC contains a 98 kb insert from chromosome 9: 27,527,137 bp to 27,625,470 bp (Human Genome, February 2009, GRCh37/hg19 ). This BAC contains 2 kb of the nearby Mps one binder kinase activator 3B (MOB3B) gene, but not the ATG initiation site for the MOB3B open reading frame (ORF), nor any portion of the neighboring interferon kappa, IFNK gene.
The substantial flanking sequence (52 kb 5 0 and 19 kb 3 0 ) of C9orf72 is likely to contain the regulatory regions needed to control expression of the sense and antisense transcripts in temporal and spatial patterns that mimic expression in the human disease. This construct was isolated from a patient-derived BAC library ( Figure S1A ) developed from a lymphoblastoid cell line (LCL) containing an expansion mutation of $1,200 repeats (Figure 1B) . Because the repeat expansion in the original 002:B7 bacterial clone was highly unstable ( Figure S1B ), we prepared 30 subcultures under different conditions and selected two subclones that retained the expansion. BAC DNA extracted from these subclones was used for pronuclear injections ( Figures  1C and S1C ). In general, smaller colonies grown at lower temperatures more efficiently retained the expansion mutation. Additionally, in both conditions, the majority of subclones showed a bimodal distribution with repeat sizes of $40 and $500. Eleven founder mice were identified; two of these contained expansions of $500 repeats and nine had shorter expansions (30-40 repeats). The number of transgene copies in these lines was estimated by southern blot using a probe outside the repeat region (data not shown). Four C9orf72 BAC lines (C9-BAC) were established for further analyses: C9-500/32 (two transgene copies, one with $500 and the other with 32 repeats), C9-500 (one copy with $500 repeats), C9-36/29 (four transgene copies with repeat sizes of 36 and 29 detected), and C9-37 (one copy with 37 repeats) ( Figures 1D, 1E , and S2A). In the multiple copy lines (C9-500/32 and C9-36/29), the transgenes always segregated together, indicating they integrated at a single insertion site. Repeat length is relatively stable in somatic tissues (brain and tail) ( Figure S2B ), and the transgene can be transmitted from generation to generation. Some intergenerational instability of the longer repeat tracts was found, which was more evident in the C9-500/32 line ( Figure S2C ). To maintain these expansion lines, we screen breeders by southern blotting and select those that maintain the long repeat.
Sense and Antisense C9orf72 Expression in C9-BAC Lines Since frontal lobe and lumbar spinal cord are prominently affected in ALS/FTD, sense and antisense transgene expression in these regions was quantified by qRT-PCR using several primer sets ( Figure 2A ; Table S1 ). Data generated using primers flanking constitutive exons 2 and 3 show that the overall levels of C9orf72 sense transcripts expressed from human BAC transgene correlate with copy number and that similar levels of the mouse C9orf72 ortholog (3110043O21Rik) relative to b-actin are found ( Figures 2B and 2C ). qRT-PCR using primers in exon 1a, designed to selectively amplify repeat-containing C9orf72 transcripts, shows that the G4C2 expansion is expressed in all four transgenic lines with the highest expression levels in the fourcopy C9-36/29 line ( Figure 2D ). Additionally, we show antisense transcripts in the frontal cortex are $40-fold higher in the C9-500/32 line and $22-fold higher in the C9-500 line compared to the C9-37 line. Antisense levels are also elevated in the fourcopy C9-36/29 line with levels $5 fold higher than the C9-37 line ( Figure 2E ). This upregulation recapitulates the increased expression of antisense transcripts ($10-to 300-fold) seen in autopsy tissue from C9(+) versus control ALS patients (Zu et al., 2013) . A similar trend of antisense upregulation (4-to 7-fold) is also seen in spinal cord in the C9-500/32 and C9-500 lines, compared to C9-37, but the overall levels are lower. These data indicate that the expansion mutation regulates antisense expression and that this upregulation is pronounced in the frontal cortex. Time course studies of C9orf72 transcripts in the C9-500 line show no significant differences in levels of expression between post-natal day (P1-P3) and 5 months of age (Figure S3A) . Similarly, no differences in expression were found between male and female expansion mice in any of the lines ( Figures S3B and S3C) .
In summary, we used endogenous human regulatory regions in a large insert BAC construct to drive expression of the C9orf72 expansion mutation in our mice. We show sense transcripts are expressed in all four lines and, similar to C9(+) patients (Zu et al., 2013) , antisense transcripts are highly upregulated in the two lines of mice with 500 repeats. or differences in weight at weaning compared to nontransgenic (NT) littermates. At 16 weeks, DigiGait analyses show transgene-positive mice from the C9-500/32 and C9-500 lines develop hindlimb gait abnormalities. Out of 42 gait parameters, mice from the C9-500/32 and C9-500 lines showed 14 and 4 significant changes compared to NT littermates, respectively. Mice from the C9-36/29 line did not show significant changes in gait at $16 weeks compared to NT animals (Table S2 ). Data from one of these gait abnormalities, increased percentage of swing time/ stride time, are shown in Figure 3A . Decreased Survival Between 20 and 40 weeks of age, a subset of female mice ($30%-35%) from the C9-500/32 and C9-500 lines develop an acute, rapidly progressive disease characterized by inactivity, labored breathing, sudden weight loss (20%-25% in 2-3 days), hindlimb weakness, paralysis, and dramatic decreases in survival compared to NT littermates (p < 0.01 and p < 0.0001, respectively) (Figures 3B-3E; Movies S1 and S2). Additionally, a subset of female mice from the high-expression four-copy C9-36/29 line show similar acute phenotypes, but with delayed onset of motor symptoms and the majority of deaths occurring later, after 40 weeks of age (p % 0.01 C9-36/29 versus NT). In contrast, female mice from the single-copy C9-37 line showed no significant differences in survival compared to NT controls ( Figure 3E ).
C9-BAC
Progressive Phenotypes
In addition to the acute disease described above, a large percentage of the remaining animals develop a milder and slower progressive disease characterized by kyphosis, reduced activity, hyperactivity when provoked, clasping, and intermittent seizures (Movie S3). These phenotypes are progressive and can, but do not necessarily, cause premature death. To quantitate the percentage of mice with these disease symptoms, we eval- of age, 35.1%, 35.7%, and 27.6% of female mice from the C9-500/32, C9-500, and C9-36/29 lines had died, and an additional 40.5%, 46.4%, and 31% had developed symptoms. No significant differences in survival were seen between animals in the C9-37 line and NT controls ( Figure 3F ). In contrast to female mice, males from the C9-500/32 and C9-500 expansion lines do not show decreased survival compared to NT males at 1 year ( Figures S4A and S4B ), but a large proportion of these animals ($43%-45%) developed phenotypes by 1 year of age (p < 0.05) ( Figures S4C and S4D) . These phenotypes were similar to those found in the slow progressive female mice. No significant differences in survival or phenotype were seen in males from the C9-36/29 or C9-37 lines compared to the NT controls ( Figure S4 ).
Open Field Analysis
Open field analyses of the older symptomatic male and female mice (1-1.5 years) and age-matched littermates show symptomatic mice spend 50% less time in the central region of the chamber compared to their asymptomatic and NT littermates, a phenotypic indication of anxiety-like behavior (Figures 3G and 3I) (Keum et al., 2016; Miller et al., 2010; Milner and Crabbe, 2008) . Additionally, a subset of these symptomatic animals showed marked decreases in ambulation ( Figures 3H and 3I) .
In summary, lines with long repeats (C9-500 and C9-500/32) show significant decreases in survival, and a large proportion of animals die or develop phenotypic abnormalities by 1 year of age (76%-82% of females and 50% of males). Additionally, decreased survival and disease phenotypes are also found in females from the high-expression four-copy C9-36/29 line, but the disease is generally later onset and less penetrant at 1 year of age compared to disease in females from the long expansion lines. In contrast, no significant phenotypic differences were found in male mice from the C9-36/29 line compared to NT males. These data indicate shorter expansions (36 and 29 repeats) at higher levels are sufficient to cause the disease in female mice. Comparisons between the C9-500 and C9-37 lines, which express C9orf72 transcripts at comparable levels, show the development of disease is length dependent. Additionally, the development of similar disease phenotypes and penetrance in the C9-500 and C9-500/32 expansion lines indicates that these phenotypes are not caused by an insertion effect.
Our subsequent analyses focused on female mice (20-40 weeks) from the C9-500/32, C9-500, and C9-36/29 lines that developed the acute, rapidly progressing disease (referred to as ''acute'') and aged (52-72 weeks) mice from the C9-500/ 32 and C9-500 lines that have slow disease progression (referred to as ''slow progressive'').
C9-BAC Mice Develop Motor Neuron Disease
To determine if the C9-BAC mice develop motor neuron disease, we examined the neuromuscular junctions in our mice. Animals with acute disease, which had reached end stage between 20 and 40 weeks, showed marked denervation of the neuromuscular junctions in the tibialis anterior (66%) and diaphragm (49%) muscles compared to 4.5% and 3.9% in NT littermates (p < 0.0001 and p = 0.02, respectively) ( Figure 4A ). No changes were found between asymptomatic C9-500 and C9-500/32 mice and age-matched NT controls ( Figure S5A ). Despite the dramatic loss of axon terminals, most neuromuscular junctions retained their normal ''pretzel-shaped'' morphology. Immunohistochemical (IHC) staining of muscle with myosin-32 antibody showed mild muscle abnormalities with focal sites of pathology. These changes include atrophic fibers, sharp angular fibers, and pyknotic nuclear clumps in fast-twitch muscle fibers, typical of denervation ( Figure S5B ). The relative preservation of the neuromuscular junction morphology and focal, but not widespread, skeletal muscle atrophy are consistent with the rapid disease progression in these mice, and suggest that neuronal loss precedes muscle pathology. In the slow progressive mice, more subtle neuromuscular junction abnormalities are seen. These include increased axonal swelling and axon terminal sprouting, indicative of degeneration and regeneration ( Figure S5C ).
To examine the motor axons projecting from the lumbar spinal cord, we quantified axonal size within the lumbar-4 (L4) ventral spinal roots. As shown in Figure 4B , acute end-stage animals have a loss of axonal integrity with increased numbers of small axons (<4 mm in diameter), indicative of degeneration and regeneration, and fewer large caliber a-axons (R4 mm in diameter). In the slower progressing animals, similar but milder phenotypes are also found in the spinal roots with an overall shift to smaller fiber sizes ( Figure S5D ).
Pathological evaluation of the ventral horn of the lumbar spinal cord in acute end-stage mice showed a significant loss in motor neurons stained by choline acetyltransferase (ChAT) ( Figure 4C) , with cresyl-violet (CV) staining of the lumbar spinal cord corroborating this finding ( Figure S6A ). Additionally, we observed atrophic and vacuolated motor neurons ( Figure 4D ). Lower motor neuron loss was also found in the slow progressing animals (Figure S6B) . Additionally, we observed degeneration, pyknosis, and vacuolization of the large pyramidal neurons in layer V of the motor cortex in acute end-stage mice, a region of the brain containing upper motor neurons ( Figure 4E ).
In summary, these results show C9-BAC mice mimic ALS with degenerative changes seen throughout the motor unit. These changes include (1) degeneration of the large pyramidal neurons in layer V of the motor cortex, (2) degeneration of the lower motor neurons that send their corresponding axons into the ventral spinal roots, and (3) degeneration of the axons that terminate in target skeletal muscles at the neuromuscular junctions.
C9-BAC Mice Show Neurodegenerative Changes Characteristic of ALS/FTD
Because the C9orf72 expansion mutation can cause both ALS and FTD, and pathology has been reported throughout the CNS, we examined our mice for additional signs of neuropathology. We found dramatic changes in acute end-stage animals (n = 6) that were not found in a large cohort (n = 16) of asymptomatic transgene-positive littermates (8-20 weeks). In acute end-stage mice, hematoxylin and eosin (H & E), and CV and NeuN staining show extensive neuronal loss, pyknosis, and abundant vacuolization in layers II/III throughout the cortex and in layer V of the motor cortex compared to NT mice (Figure 5A) . Quantification of CV-stained neurons showed $75% decrease in layer II/III neurons and $57% decrease in layer V of the motor cortex ( Figure 5B ). In contrast, no overt differences in the cortex were found by CV staining in asymptomatic C9-500 and C9-500/32 mice at 2 or 5 months of age ( Figure S6C ).
Because pathological changes in the hippocampus have been reported in C9orf72 autopsy cases (Pletnikova et al., 2014) , we looked at the hippocampal region in our mice using NeuN and CV staining. These experiments show dramatic loss of neurons in cornu ammonis (CA) and dentate gyrus (DG) regions of the hippocampus, with the patterns of neurodegeneration varying substantially between animals. Some animals showed marked degeneration of the CA1 region and others showed degeneration of the CA3 and DG, or the entire CA region ( Figures 5C and S6D ). These data are consistent with the variability of hippocampal neurodegeneration in human C9 (+) autopsy cases and the patchy accumulation of C9orf72 RAN proteins (Pletnikova et al., 2014; Zu et al., 2013) .
Additionally, we examined the neuroinflammatory response that may be triggered in response to extensive neurodegeneration. Acute end-stage mice show increased Iba1 staining of phagocytic microglia in the hippocampus compared to NT controls, suggesting this region is actively undergoing neurodegeneration at the time of death (Figures 5D and S6E ). In addition, GFAP staining shows prominent astrocytosis in layers I-III and layer V of the motor cortex and the hippocampus compared to NT controls ( Figures 5E, 5F , and S6F). These findings are consistent with reactive gliosis triggered in response to neurodegeneration. Cerebellar atrophy has been reported both in autopsy tissue and through neuroimaging of patients with C9orf72 expansions (Mahoney et al., 2012; Whitwell et al., 2012) . Examination of the cerebellum in acute end-stage mice shows a 65% loss of D28K-calbindin-positive Purkinje cells and a 28% decrease in thickness of the molecular layer compared to controls ( Figures  6A-6C) .
In addition to the ChAT-positive motor neurons ( Figure 4C ), NeuN-and CV-positive neurons in the lateral and posterior horns of the spinal cord that predominantly contain interneurons were also decreased in the acute end-stage animals compared to NT controls ( Figures 6D, 6E , and S6A), suggesting the possible involvement of these interneurons in disease. In contrast to the acute end-stage animals, male and female mice with slowly progressive disease showed milder neurodegenerative changes. For example, at 18 months of age the slowly progressive animals showed focal rather than widespread degenerative changes in the neocortex, milder degenerative changes in the cerebellum, and no overt degeneration in the hippocampus (Figures S7A-S7D ).
Taken together, these results indicate that acute end-stage C9-BAC mice have widespread neurodegenerative changes in the neocortex, hippocampus, cerebellum, and spinal cord. In contrast, the slowly progressive mice show loss of motor neurons in the spinal cord, focal sites of neurodegeneration in the neocortex, and milder degeneration of the cerebellum with relative sparing of the hippocampus.
C9-BAC Mice Show Molecular Hallmarks of ALS/FTD
Next, we tested if our BAC transgenic mice have hallmark molecular features of C9orf72 ALS/FTD. We focused our analysis on the motor cortex, hippocampus, cerebellum, and spinal cord. We show by fluorescence in situ hybridization (FISH) that sense and antisense RNA foci accumulate in mice from the C9-500 and C9-500/32 lines as early as 2 months of age, but not in C9-36/29, C9-37, or NT controls (see examples in Figures 7A and S8) . We used RNA foci in the long repeat lines as a marker of sense and antisense transcript distribution to begin to understand if sense or antisense transcripts or their corresponding RAN proteins are preferentially found in affected regions of the brain and spinal cord. Sense foci are found throughout the brain in nearly all NeuN-positive neuronal cells and also in a large portion of NeuN-negative cells (glia) in 2-month-old animals (Table 1 ). In contrast, antisense foci show a more specific pattern of accumulation in regions of the brain and spinal cord that degenerate. For example, abundant antisense foci are found in upper motor neurons in layer V of the motor cortex, CA and DG neurons in the hippocampus, and cerebellar Purkinje cells and interneurons in lateral and posterior horn of spinal cord. Moderate levels of antisense foci were found in layers II/III of the motor cortex and were occasionally seen in the layer IV of the motor cortex and the cerebellar granule and molecular layers. Different from sense foci, antisense foci were not apparent in glia throughout the CNS or ChAT-positive motor neurons in the spinal cord ( Figure S8 ; Table 1 ). No overt differences in sense and antisense RNA foci were observed in 2-month-old asymptomatic mice compared with acute end-stage mice (5-7 months) ( Figures S8 and S9 ) or older slowly progressive mice ($18 months) (data not shown).
An additional hallmark of C9orf72 ALS/FTD is the accumulation of RAN protein aggregates. In comparison to human autopsy tissue (Zu et al., 2013) , detecting RAN protein aggregates in our mice was more challenging, possibly because the aggregates are smaller and have less time to develop during the shorter lifespan of mice. To improve RAN protein detection in our mice, we generated a novel monoclonal poly-GA antibody (27B11), which is highly specific for aggregated poly-GA protein ( Figure S10) . IHC staining using 27B11 shows small poly-GA aggregates throughout the brain in all three phenotypic lines (C9-500/32, C9-500, and C9-36/29), but not in NT controls (Figures 7B and S11A) . In contrast, poly-GA aggregates were not detected in the C9-37 repeat line. Consistent with previous studies (Zu et al., 2011 (Zu et al., , 2013 , these data indicate that increased repeat length favors RAN protein accumulation (C9-500 GA(+) versus C9-37 GA(À)) and also that repeats of $36 are sufficient to trigger in vivo accumulation of RAN proteins if expression levels are sufficiently high (C9-36/29 GA(+) versus C9-37 GA(À)). Additionally, we also detected poly-GP aggregates in the neocortex and thalamus of acute end-stage mice from the C9-500/32 and C9-500 lines ( Figures 7C and S11B ). To correlate RAN protein accumulation with disease, we compared poly-GA RAN protein aggregates in asymptomatic and symptomatic mice from the C9-500 line. In general, poly-GA RAN protein aggregates are abundant in acute end-stage and older mice but difficult to find in asymptomatic mice. Because the first region of the brain to show robust poly-GA accumulation is the retrosplenial cortex, we chose this region to correlate poly-GA RAN protein accumulation with age and disease status ( Figure 7D ). In asymptomatic animals at 2 months of age, poly-GA RAN protein aggregates in the retrosplenial cortex can be detected as infrequent, small, pin-like dots. At 5-7 months of age, asymptomatic mice have more pin-like poly-GA aggregates. In acute end-stage animals of the same age (5-7 months), the poly-GA aggregates are larger. Finally, in 18-month slow progressive mice, poly-GA aggregates are more abundant and larger ( Figure 7D ). These results demonstrate that the frequency and size of RAN protein aggregates increase with age and disease. The retrosplenial cortex was also positive for p62, a marker of autophagy ( Figure S11C ). TDP-43 inclusions are a neuropathological feature found in >90% of ALS and 50% of FTD autopsy cases, including C9orf72 ALS/FTD (Ling et al., 2013) . TDP43 staining in our C9-BAC mice shows nuclear and cytoplasmic aggregates in degenerating neurons throughout the brain, including the hippocampus and levels II/III and V of the motor cortex ( Figure 7E ). These changes are found in the acute end-stage animals from the C9-500, C9-500/32, and C9-36/29 lines, but not in asymptomatic or control animals ( Figure S11D ).
In summary, C9-BAC mice show C9 ALS/FTD hallmark molecular features of C9orf72 ALS/FTD. Sense and antisense RNA foci accumulate in the brain and spinal cord in distinct patterns. RAN protein aggregate load increases with age and disease. TDP43 aggregation characteristic of ALS/FTD and other neurodegenerative diseases is found in acute end-stage C9-BAC mice.
DISCUSSION
We have developed a BAC transgenic model of C9orf72 ALS/ FTD in which the expression of the expansion mutation is driven by the endogenous human regulatory regions. Our model shows pleomorphic phenotypes including paralysis, anxiety-like behavior, decreased survival, and widespread neurodegeneration of the brain and spinal cord. Paralyzed mice showed degeneration of spinal motor neurons with significant cortical and hippocampal degeneration. Mice that do not develop the paralytic phenotype had less-severe degeneration in the brain and spinal cord. Similar to C9orf72 patients (Zu et al., 2013) , affected lines of mice show elevated antisense transcripts, RAN proteins, and TDP43 aggregates. These mice provide the first model that enables molecular dissection of the basis for clinically relevant phenotypes for C9orf72 ALS and for testing the efficacy of therapeutic strategies.
Our C9-BAC mouse model provides insight into the mechanisms of C9orf72 ALS/FTD. First, our finding that the human C9orf72 containing BAC causes disease in a repeat-length and expression-dependent manner argues for gain-of-function and against loss-of-function mechanisms. These data are consistent with separate experiments showing the absence of typical disease phenotypes in C9orf72 knockout mice (Koppers et al., 2015) . Second, the phenotypes in our C9-36/29 line indicate that relatively short repeats, expressed at even moderately elevated levels, are sufficient to trigger disease. Although RNA foci are not present in the C9-36/29 mice, it is still possible that RNAs with moderate expansions sequester key RNA binding proteins and result in RNA processing abnormalities. Third, RAN protein accumulation correlates with disease severity in our C9-BAC mice. RAN proteins were found in all three phenotypic lines, including the C9-36/29, but not the C9-37, line. While these data suggest RAN protein accumulation may play an important role in disease, better antibodies and additional studies will be required to understand the role of sense and antisense RAN proteins in the disease onset and progression. Finally, the detection of TDP-43 pathology in acute end-stage mice mimics the TDP-43 aggregates present in C9orf72 ALS/ FTD patients and more than 90% of all ALS cases. Because TDP43 aggregates are only detected in highly degenerated regions in acute end-stage animals, it is not yet clear if TDP43 aggregation causes the degenerative changes or is a downstream result of neuronal degeneration. The development of interventions that target individual pathologies should allow for a better understanding of the time course of disease and events that mediate the different phenotypic aspects of our model.
Acute end-stage C9-BAC mice develop key neuropathological features of both ALS and FTD. Consistent with ALS, our mice show degeneration of the entire motor unit including neurons in the motor cortex and the lumbar spinal cord, ventral roots, and neuromuscular junctions of the TA and diaphragm. While degeneration of the ventral roots is statistically significant, the degeneration of the motor neurons and the denervation of the neuromuscular junctions are more dramatic. Given how quickly the acutely affected animals decline, it is possible that atrophied axons may linger for some period after the cell body and neuromuscular junction have degenerated, producing the data we observe. Pathological features of FTD include neurodegeneration of the hippocampus and pyramidal neurons of the frontal cortex (Kril and Halliday, 2011; Lashley et al., 2015) . A typical feature of FTD is neuronal loss in layers II/III, which is often associated with mild to moderate spongioform changes and reactive gliosis (Seltman and Matthews, 2012; Thompson and Vinters, 2012) . Similar to FTD patients, acute end-stage C9-BAC mice have striking neurodegeneration of cortical layers II/III, as well as the hippocampus, with widespread pyknotic nuclei, vacuolization, and gliosis. A recently appreciated feature of C9orf72 ALS/FTD is cerebellar atrophy and pathology (Al-Sarraj et al., 2011; Gendron et al., 2015; Mahoney et al., 2012; Yokoyama and Rosen, 2012) . Our mice also model this aspect of the disease and show Purkinje cell degeneration and thinning of the molecular layer. Cerebellar changes may underlie the gait abnormalities, one of the earliest phenotypes found in our mice. In summary, the neurodegenerative and neuroinflammatory changes in our C9-BAC mice are consistent with the neuropathological features of the human disease and are likely to underlie the paralysis, respiratory dysfunction, and anxiety-like phenotypes found in our mice.
In contrast to the acute end-stage mice, animals with slow progressive phenotypes show only focal degeneration of the cortex, milder Purkinje cell loss, relative sparing of the hippocampus, and compensatory neuronal sprouting at the neuromuscular junctions. These milder neurodegenerative changes are consistent with the longer lifespan of the slow progressive animals compared to animals with acute disease.
Although the slow progressive disease phenotypes are fairly penetrant in males and females, the acute rapidly progressing phenotype was found in female, but not male mice. While we do not yet understand the molecular basis for this difference, hormonal regulation or sex-specific differences in inflammatory responses to RAN proteins may be contributing factors. Interestingly, a higher frequency of the more rapidly progressive, bulbaronset ALS has been reported in female patients (63%) and in C9orf72 ALS Turner et al., 2010) .
Bidirectional expression of expansion mutations is now a common theme in microsatellite expansion diseases (Batra et al., 2010; Cho et al., 2005; Moseley et al., 2006) . Similar to the elevated levels of C9orf72 antisense transcripts seen in C9 (+) patient brains (Zu et al., 2013) , antisense transcripts are also elevated in our expansion mice. The elevated levels of antisense expression in our C9-BAC mice ( Figure 2E ) suggest that the expansion mutation promotes antisense transcription, possibly by increasing chromatin accessibility to the transcriptional machinery.
Similar to C9orf72 autopsy cases (Cooper-Knock et al., 2015) , sense and antisense foci show differences in distribution in brain and spinal cord in the C9-500 and C9-500/32 lines. Sense foci are widespread and abundant throughout the CNS and are found in regions of the brain that are susceptible and resistant to neurodegeneration. In contrast, antisense foci are primarily found in vulnerable regions of the CNS, including layers II/III and V of the cerebral cortex, the DG and CA regions of the hippocampus, and cerebellar Purkinje cell layer. A notable exception to this trend is in the spinal cord. Only sense foci were detected in motor neurons, while both sense and antisense foci were found in interneurons. Since both types of neurons degenerate, three possibilities arise: (1) motor neurons may be more susceptible to sense RNA than neurons in the rest of the CNS; (2) motor neurons in our mice express toxic antisense RNAs, but not the key RNA binding proteins required to sequester the antisense RNA into foci; and (3) antisense expression first affects the inhibitory interneurons, and loss of inhibitory input from the interneurons causes excitotoxicity and motor neuron death through a non-cell-autonomous process. Additionally, neurodegeneration of the interneurons containing antisense RNA indicates that the role of the interneurons in C9 ALS pathology may be underappreciated. These data and other evidence from cell culture and Drosophila models (Mizielinska et al., 2014; Wen et al., 2014) suggest that antisense transcripts and/or the corresponding antisense RAN proteins may be critical drivers of the disease.
In C9orf72 autopsy tissue, RAN proteins show a patchy and variable pattern of RAN protein accumulation (Pletnikova et al., 2014; Zu et al., 2013) . In Huntington's disease, RAN protein accumulation occurs in a cell-type-specific manner, which is independent from the polyGln (Bañ ez-Coronel et al., 2015) . In addition to cell-specific RNA gain-of-function mechanisms, it is possible that focal accumulation of one or more RAN proteins may underlie neurodegeneration, including the remarkably variable degenerative changes seen in the hippocampi of our mice. While further work is needed to understand the role of sense and antisense RNAs and RAN proteins in ALS/FTD, most therapeutic efforts for microsatellite expansion diseases have targeted the sense gene products (Hu et al., 2012; Kordasiewicz et al., 2012; Lagier-Tourenne et al., 2013; Wheeler et al., 2012) . Since most of these diseases are late onset, therapeutic benefit may be achieved by targeting sense transcripts and lowering the burden of sense RNAs and RAN proteins. It is also possible that targeting the sense transcripts will lower or increase the steady-state levels of antisense transcripts (Sopher et al., 2011 ). An additional therapeutic approach would be to block the factors involved in RAN translation without affecting canonical translation.
Recently, two other groups reported the development of C9orf72 BAC transgenic models (O'Rourke et al., 2015; Peters et al., 2015) . Although these animals show sense and antisense RNA foci and the accumulation of the GP RAN protein, surprisingly, neither of these models developed phenotypic or neurodegenerative features of the disease. Possible explanations for this difference include (1) the absence of the full-length gene and 3 0 UTR regulatory region in one model (Peters et al., 2015) ; (2) differences in cis modifiers on the individual BAC transgenes; (3) differences in mouse genetic backgrounds, which have been previously reported to affect phenotypes in other neurodegenerative diseases (Hsiao et al., 1995; Strong et al., 2012) ; and (4) differences in transgene expression levels or spatial/temporal expression patterns. Detailed, side-by-side comparisons of these C9orf72 BAC models may reveal new insight into ALS/ FTD pathogenesis.
ALS and FTD are devastating and fatal neurodegenerative diseases. Efforts to develop therapeutic strategies have been hampered by the complexity of disease mechanisms. Our mice are the first to develop the molecular, behavioral, and neurodegenerative features of C9orf72 ALS/FTD. Antisense transcripts in these mice are upregulated and preferentially accumulate in cell populations vulnerable to neurodegeneration. Additionally, RAN protein accumulation increases with age and disease severity. Taken together, these data support a model in which antisense transcripts and/or RAN proteins are critical drivers of disease pathogenesis. These mice provide an important tool that can be used to tease apart the most important molecular mechanisms of this complex disease and test the efficacy of therapeutic strategies, not just by reversing one or more molecular markers of disease, but by reversing the disease itself.
EXPERIMENTAL PROCEDURES
A BAC library from a patient-derived LCL was generated. BAC clones were screened by DNA dot blot analysis with a DNA probe targeting the C9orf72 gene. Four BAC transgenic lines were established after pronuclear injection. Molecular studies including southern blot, PCR, repeat-primed PCR, and qRT-PCR were performed to characterize transgene copy number and sense and antisense expression levels. Gait analyses, grip strength, cage behavior, and open field testing were done to look for ALS and FTD phenotypes. Histological analyses included assessment of neuromuscular junctions in the tibialis and diaphragm muscles, quantification of motor neuron ventral roots, and immunohistochemistry of the brain and spinal cord using a variety of antibodies. Assessment of RNA foci and colocalization with neurons (Neu-N) in the brain or lower motor neurons (ChAT) in the spinal cord were performed. See Supplemental Experimental Procedures for additional details.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures, eleven figures, two tables, and three movies and can be found with this article online at http://dx.doi.org/10.1016/j.neuron.2016.04.005.
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